Gary O'Hara Named Chief Technology Officer at Sanomedics
Gary O'Hara Named Chief Technology Officer at Sanomedics
Co-founded Intelligent Medical Systems
MIAMI, Aug 31, 2010 (BUSINESS WIRE) -- --Invented the first commercialized infrared tympanic thermometer (FirstTemp(R) and Genius(R) brands)
--Co-founded Tryom Inc., creating acclaimed backgammon, chess and contract bridge games
--Member of venture capital firm Tech Coast Angels, providing business acumen and financing to early stage technology and biomedical companies
Keith Houlihan, Co-founder and President of Sanomedics International Holdings (Pink Sheets: SIMH), today announced that Gary O'Hara has been named Chief Technology Officer for Sanomedics International Holdings. Mr. O'Hara brings over 25 years of leading medical and technological product innovation and business development experience to the Sanomedics team.
"Gary is a successful entrepreneur and one of the brightest creative innovators in the field today as evidenced by the numerous medical devices he has created, as well as the technological patents he holds for personal information devices and gaming applications," said Keith Houlihan, Co-founder and President. "Gary will be responsible for leading the Sanomedics development team and brings a wealth of experience which we believe will make us the leading home medical device company in the world."
Mr. O'Hara was the co-founder of Intelligent Medical Systems (IMS) and built the company to more than 200 employees while making "Inc. 500's" list of fastest growing U.S. private companies. He invented the first commercialized infrared tympanic thermometer (FirstTemp(R) and Genius(R) brands) for which he was cited as Inventor of the Year by the San Diego Patent Law Association. In 1993, the Company was acquired by Fortune 500 pharmaceutical manufacturer American Home Products. Prior to his work in the medical device industry, he co-founded Tryom, Inc. which was a developer and manufacturer of handheld personal information devices and electronic games of strategy such as backgammon, chess and contract bridge. Mr. O'Hara has also been active in the seed and startup phases of many ventures through his involvement with the Tech Coast Angels which is an organization of 150 investors that invest in and mentor early stage technology and biomedical companies. Mr. O'Hara holds numerous patents related to medical devices and electronic computer games and holds B.S. and M.S. degrees in Electrical Engineering from the University of Michigan as well as an MBA from Eastern Michigan University.
"Gary's coming to Sanomedics represents a milestone in our growth as an international company dedicated to providing easy to use and effective medical diagnostic devices that will have a positive impact on the way in which medical care is delivered anywhere in the world, whether in clinics, hospitals or the patient's home," said Craig Sizer, Co-Founder and Chairman. "Gary provides us with a wealth of technological experience and knowledge that will surely lead to needed innovative medical devices that positively impact the lives of people on a daily basis."
About Sanomedics
Sanomedics International Holdings, Inc. (SIMH) manufactures and distributes innovative professional medical, as well as, home health diagnostic devices and products. As a pioneer in the trend toward preventive medicine, Sanomedics' goal is to act as a bridge between the high-technology medical world and the home healthcare environment. All Sanomedics professional and home healthcare diagnostic products are extremely easy to use, while providing accurate results in less than one second.
Forward Looking Statements
This press release may contain statements which constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the intent belief or current expectations of the Company, its directors, or its officers with respect to the future operating performance of the Company Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those in the forward-looking statements as a result of various factors. The Company's periodic filings with the Securities and Exchange Commission should be viewed for a complete understanding of risk and uncertainty.
www.sanomedics.com
(C)2010 Sanomedics International Holdings Inc. All rights reserved.
SOURCE: Sanomedics International Holdings
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
